OAMU
GILD icon

Ostrum Asset Management US’s Gilead Sciences GILD Stock Holding History

Ostrum Asset Management US’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$9.96M Sell
153,206
-99,932
-39% -$6.64M 2.77% 16
2018
Q4 		$15.8M Buy
+253,138
New +$17.7M 2.33% 12

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Ostrum Asset Management US's GILD Position: Q1 2019 in Review

Ostrum Asset Management US reduced its Gilead Sciences (GILD) stake by 39% in Q1 2019, selling an estimated $6.64M and leaving 153,206 shares worth $9.96M. The position accounts for 2.77% of the portfolio, ranked #16.

Ostrum Asset Management US first reported a position in GILD in Q4 2018 and has held it in 2 quarters since. The position peaked at $15.8M in Q4 2018. 1,493 funds tracked by Wall St. Rank hold GILD as of Q1 2019.

  • Ostrum Asset Management US held 153,206 shares of Gilead Sciences worth $9.96M as of Q1 2019.
  • Ostrum Asset Management US sold 99,932 Gilead Sciences shares in Q1 2019, an estimated $6.64M.
  • Gilead Sciences made up 2.77% of Ostrum Asset Management US's portfolio in Q1 2019, its #16 holding.
  • Ostrum Asset Management US first reported a position in Gilead Sciences in Q4 2018 and has held it in 2 quarters since.
  • Ostrum Asset Management US's Gilead Sciences position peaked at $15.8M in Q4 2018.
  • 1,493 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2019.

Based on Ostrum Asset Management US's 13F filing for Q1 2019, filed 15 May 2019.